New triple therapy aims to reverse heart damage in stiff heart condition
NCT ID NCT06655480
First seen Apr 24, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests whether a combination of three heart medications (SGLT2 inhibitor, ARNI, and MRA) can improve heart structure, function, and daily life in people with advanced heart failure with preserved ejection fraction (HFpEF). Fifty participants will receive either the triple therapy or standard care for 52 weeks. The goal is to see if the triple therapy reduces heart scarring and improves exercise ability and symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
RECRUITINGMoscow, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.